复方鳖甲软肝片联合恩替卡韦治疗慢性乙型肝炎肝硬化代偿期临床研究  

Clinical Study on Compound Biejia Ruangan Tablets Combined with Entecavir for Compensated Cirrhosis due to Chronic Hepatitis B

作　　者：相维婷 余松[1] 曾瑞琦 XIANG Weiting;YU Song;ZENG Ruiqi(Department of Infectious Diseases,The First People's Hospital of Huzhou,Huzhou Zhejiang 313000,China)

机构地区：[1]湖州市第一人民医院感染科,浙江湖州313000

出　　处：《新中医》2024年第1期83-87,共5页New Chinese Medicine

摘　　要：目的:观察复方鳖甲软肝片联合恩替卡韦治疗慢性乙型肝炎肝硬化代偿期的疗效,分析该治法对患者肝功能、纤维化指标的影响。方法:选择70例慢性乙型肝炎肝硬化患者为研究对象,按照自愿原则分为恩替卡韦组和鳖甲软肝组各35例。恩替卡韦组予以恩替卡韦片治疗,鳖甲软肝组在恩替卡韦组的基础上予以复方鳖甲软肝片治疗。比较2组临床疗效、不良反应,比较2组治疗前后肝功能、肝纤维化指标。结果:2组治疗总有效率、不良反应总发生率比较,差异均无统计学意义(P>0.05)。治疗后,2组总胆红素(TBil)、丙氨酸转移酶(ALT)及天门冬氨酸转移酶(AST)水平均下降(P<0.05),且鳖甲软肝组低于恩替卡韦组(P<0.05)。治疗后,2组透明质酸(HA)、层粘蛋白(LN)以及Ⅲ型前胶原(PcⅢ)水平均下降(P<0.05),且鳖甲软肝组低于恩替卡韦组(P<0.05),2组Ⅳ型胶原(Ⅳ-C)水平均升高(P<0.05),且鳖甲软肝组高于恩替卡韦组(P<0.05)。治疗后,2组肝脏弹性硬度明显下降(P<0.05),且鳖甲软肝组低于恩替卡韦组(P<0.05)。结论:复方鳖甲软肝片联合恩替卡韦能够明显改善慢性乙型肝炎肝硬化患者的肝功能,并抑制和逆转肝纤维化进程,且不增加不良反应。Objective:To observe the curative effect of Compound Biejia Ruangan Tablets combined with Entecavir on compensated cirrhosis due to chronic hepatitis B and analyze its effect on liver function and hepatic fibrosis indexes of patients.Methods:A total of 70 cases of patients with compensated cirrhosis due to chronic hepatitis B were selected as the study objects and divided into the Entecavir group and the Biejia Ruangan group on a voluntary basis,with 35 cases in each group.The Entecavir group was treated with Entecavir Tablets,and the Biejia Ruangan group was additionally treated with Compound Biejia Ruangan Tablets based on the treatment of the control group.The treatment lasted for half a year.Clinical effects and the incidence of adverse reactions were compared between the two groups.Liver function and hepatic fibrosis indexes were compared before and after treatment between the two groups.Results:There was no significant difference being found in the comparison of the total effective rates and the total incidence of adverse reactions between the two groups(P>0.05).After treatment,the levels of total bilirubin(TBil),alanine transferase(ALT),and aspartate transferase(AST)in the two groups were decreased(P<0.05),and the three levels in the Biejia Ruangan group were lower than those in the Entecavir group(P<0.05).After treatment,the levels of hyaluronic acid(HA),laminin(LN),and typeⅢprocollagen(PcⅢ)in the two groups were decreased(P<0.05),and the three levels in the Biejia Ruangan group were lower than those in the Entecavir group(P<0.05);the levels of typeⅣcollagen(Ⅳ-C)in the two groups were increased(P<0.05),and the level in the Biejia Ruangan group was higher than that in the Entecavir group(P<0.05).After treatment,the liver elasticity and stiffness in the two groups were significantly decreased(P<0.05),and the liver elasticity and stiffness in the Biejia Ruangan group were lower than those in the Entecavir group(P<0.05).Conclusion:Compound Biejia Ruangan Tablets combined with Entecavir can significant

关 键 词：慢性乙型肝炎 肝硬化代偿期 复方鳖甲软肝片 肝功能 肝纤维化 

分 类 号：R512.62[医药卫生—内科学] R575.2[医药卫生—临床医学]